Compare MLP & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLP | NBP |
|---|---|---|
| Founded | 1909 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.5M | 275.2M |
| IPO Year | 2010 | N/A |
| Metric | MLP | NBP |
|---|---|---|
| Price | $17.00 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 10.9K | ★ 1.1M |
| Earning Date | 05-14-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,457,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.24 | N/A |
| 52 Week Low | $13.84 | $1.67 |
| 52 Week High | $20.34 | $5.19 |
| Indicator | MLP | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 66.26 | 24.27 |
| Support Level | $16.58 | N/A |
| Resistance Level | $17.49 | $2.73 |
| Average True Range (ATR) | 0.47 | 0.13 |
| MACD | 0.17 | -0.04 |
| Stochastic Oscillator | 63.12 | 10.67 |
Maui Land & Pineapple Co Inc is a landholding and operating parent company that owns land and commercial property on the island of Maui, Hawaii. The Company puts its assets into productive use by planning, managing, developing, and selling residential, resort, commercial, agricultural, and industrial real estate. Its segments include land development and sales, which cover land planning, entitlement, development, construction, and sales of land assets; leasing, which generates revenue from real property leasing, license fees and royalties, and includes maintenance of real estate assets, conservation activities, and management of water systems in West and Upcountry Maui; and resort amenities, which include a membership program offering benefits within the Kapalua Resort.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.